PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Shahneen Sandhu; M. Hussain; J. Mateo; Khawla El Fizazi; F. Saad; N. Shore; K. Chi; O. Sartor; N. Agarwal; D. Olmos; A. Thiery-Vuillemin; P. Twardowski; Niven Mehra; C. Goessl; J. Kang; J. Burgents; W. Wu; A. Kohlmann; C. Adelman; J. de Bono

doi:10.1093/annonc/mdz446.007

Article2019

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Maha Hussain, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, K.N. Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, P. Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Weiwen Wu, Alexander Kohlmann, Carrie A. Adelman, Johann S. de Bono

Article2017

PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.

Johann S. de Bono, Maha Hussain, Antoine Thiery-Vuillemin, Joaquı́n Mateo, Oliver Sartor, Kim N., Karim Fizazi, Przemyslaw Twardowski, Neeraj Agarwal, Shahneen Sandhu, David Olmos, Neal D. Shore, Fred Saad, Sherry Liu, Carsten Goessl, Joe Burgents

Article2020

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain

Article2022

Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman,

Preprint2023

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman,

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Discussion(0)

Related publications

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Discussion(0)

Related publications

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Tumor Genomic Testing for &amp;gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Data from Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)